WO1997023455A1
(en)
*
|
1995-12-21 |
1997-07-03 |
Eli Lilly And Company |
Processes for preparing non-peptidyl tachykinin receptor antagonists
|
AU2898297A
(en)
*
|
1996-05-24 |
1998-01-05 |
Novartis Ag |
Use of substance p antagonists for treating social phobia
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
AU726745B2
(en)
*
|
1996-10-07 |
2000-11-16 |
Merck Sharp & Dohme Limited |
CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
EP0942733B1
(en)
*
|
1996-12-02 |
2005-04-27 |
MERCK SHARP & DOHME LTD. |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
AU731349B2
(en)
*
|
1996-12-02 |
2001-03-29 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating sexual dysfunctions
|
ATE282417T1
(en)
*
|
1996-12-02 |
2004-12-15 |
Merck Sharp & Dohme |
THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOVEMENT DISORDERS
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
AU731672B2
(en)
*
|
1996-12-02 |
2001-04-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
ES2231901T3
(en)
*
|
1996-12-02 |
2005-05-16 |
MERCK SHARP & DOHME LTD. |
USE OF NK-1 RECEIVER ANTAGONISTS TO TREAT DISORDERS FOR THE USE OF SUBSTANCES.
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
JP2001524960A
(en)
*
|
1997-04-24 |
2001-12-04 |
メルク シヤープ エンド ドーム リミテツド |
Use of an NK-1 receptor antagonist to treat an eating disorder
|
CA2287397A1
(en)
*
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of an nk-1 receptor antagonist and an ssri for treating obesity
|
AU8297698A
(en)
*
|
1997-07-10 |
1999-02-08 |
Eli Lilly And Company |
Inhibitors of neutrophil mediated oxidant production
|
WO1999007375A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
JP2001513562A
(en)
*
|
1997-08-28 |
2001-09-04 |
メルク エンド カムパニー インコーポレーテッド |
How to treat premenstrual or late luteal syndrome
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
GB9812662D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
PT1107744E
(en)
|
1998-08-25 |
2003-08-29 |
Wolfgang Mueller |
USE OF ANTAGONISTS OF THE P-SUBSTANCE FOR THE TREATMENT OF CHRONIC FAILURE SYNDROME AND / OR FIBROMYALGIA
|
AR021155A1
(en)
*
|
1999-07-08 |
2002-06-12 |
Lundbeck & Co As H |
TREATMENT OF NEUROTIC DISORDERS
|
ATE318135T1
(en)
|
1999-09-03 |
2006-03-15 |
Apbi Holdings Llc |
USE OF DAPOXETINE, A RAPID ONSET SELECTIVE SEROTONIN UPtake INHIBITOR, FOR THE TREATMENT OF SEXUAL DYSFUNCTION
|
CA2324813A1
(en)
*
|
1999-11-10 |
2001-05-10 |
Susan Beth Sobolov-Jaynes |
Combination treatment for depression and anxiety
|
AUPQ514600A0
(en)
*
|
2000-01-18 |
2000-02-10 |
James Cook University |
Brain injury treatment
|
CA2412355A1
(en)
*
|
2000-06-12 |
2001-12-20 |
University Of Rochester |
Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
|
WO2003101459A1
(en)
*
|
2002-05-29 |
2003-12-11 |
The Regents Of The University Of California |
Antagonizing nk1 receptors inhibits consumption of substances of abuse
|
FR2912057B1
(en)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR
|
CA2655212C
(en)
|
2006-06-16 |
2012-07-31 |
H. Lundbeck A/S |
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
GB0708186D0
(en)
*
|
2007-04-27 |
2007-06-06 |
Merck Sharp & Dohme |
Therapeutic compounds
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|